Virginia Commonwealth University
COST-EFFECTIVENESS ANALYSIS OF DIRECT-ACTING ANTIVIRAL STRATEGIES FOR HEPATITIS C POSITIVE DONOR TO NEGATIVE RECIPIENT KIDNEY TRANSPLANTATION
Abstract
dc:description.abstract<p><strong>Background. </strong>Short-duration direct-acting antiviral (DAA) administration achieves sustained virologic response in hepatitis C virus (HCV)-positive donor to negative recipient (D+/R−) kidney transplants; however, the cost-effectiveness of the DAA strategies has not been comprehensively evaluated using contemporary real-world transmission data and the most recent drug pricing. We sought to determine the most cost-efficient DAA strategy using data from the Ultra-short <strong>D</strong>irect acting <strong>A</strong>nti-viral <strong>P</strong>rophylaxis to <strong>P</strong>r<strong>e</strong>vent virus transmission from hepatitis C viremic donors to hepatitis C negative kidney transplant <strong>R</strong>ecipients (DAPPeR) trial experience of 204 consecutive D+/R− kidney transplants and current drug acquisition costs, comparing it to other published strategies.</p> <p><strong>Methods. </strong>We developed a decision model to estimate the cost-effectiveness of several DAA strategies from the perspective of the health system. In this analysis, we compared 5 DAA strategies: (1) 7-day sofosbuvir/velpatasvir (SOF/VEL); (2) 8-day glecaprevir/pibrentasvir (G/P); (3) 4-week SOF/VEL; (4) 8-week G/P transmit-and-treat; and (5) 14-day G/P regimen. Drug costs were informed by wholesale acquisition cost (WAC) minus an assumed 30% institutional discount. Transition probabilities were derived from published clinical trials and the expanded DAPPeR study of 204 consecutive D+/R− kidney transplants. The outcome was defined as no HCV infection after each respective DAA administration.</p> <p><strong>Results. </strong>Strategy 2 (8-day G/P) was the least costly intervention (EEC: $2,640) with a 100% success rate, followed by Strategy 1 (7-day SOF/VEL; EEC: $5,273), Strategy 5 (14-day G/P; EEC: $5,544), Strategy 3 (4-week SOF/VEL; EEC: $5,600), and Strategy 4 (8-week G/P transmit-and-treat; EEC: $18,480). All short-duration treatment strategies were substantially less expensive than transmit-and-treat, with savings ranging from $12,880 to $15,840 per transplanted patient.</p> <p><strong>Conclusions. </strong>Short-duration DAA using 8-day G/P or 7-day SOF/VEL is the most cost-effective approach for HCV D+/R− kidney transplants. The choice between these strategies is sensitive to institution-specific drug pricing and real-world transmission rates, underscoring the need for individualized economic evaluations.</p>
Degree
thesis:*- Name thesis:degree_name
- Master of Science
- Level thesis:degree_level
- Thesis
- Discipline thesis:degree_discipline
- Pharmaceutical Sciences
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Yakubu, Idris
- https://orcid.org/0000-0002-7871-3479
- Contributors dc:contributor
-
- Vasco Pontinha
Subjects
dc:subject × 8Rights
dc:rights- Statement dc:rights
-
- © The Author
Identifiers
dc:identifier.*- Repository record dc:identifier
- https://scholarscompass.vcu.edu/etd/8509